Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer

FASEB Journal

Volumn 25, Issue 10, 2011, Pages 3325-3335

  Schulz, Petra ^a   Fischer, Christian ^a   Detjen, Katharina M ^a   Rieke, Svenja ^a   Hilfenhaus, Georg ^a   Von Marschall, Zofia ^a   Böhmig, Michael ^a   Koch, Inga ^a   Kehrberger, Jenny ^a   Hauff, Peter ^b   Thierauch, Karl Heinz ^b   Alves, Frauke ^c   Wiedenmann, Bertram ^a   Scholz, Arne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Animal model; Lymphangiogenesis; Orthotopic

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CELL MOTILITY; CONTROLLED STUDY; DENSITY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; NONHUMAN; PANCREAS CARCINOMA; PANCREAS DUCT ADENOCARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; STIMULATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; AGED; ANGIOPOIETIN-2; ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTOR, TIE-2; RNA, MESSENGER;

ANIMALIA;

EID: 80053925054     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-182287     Document Type: Article

References (53)

1. Ghaneh, P., Costello, E., and Neoptolemos, J. P. (2007) Biology and management of pancreatic cancer. Gut 56, 1134-1152 (Pubitemid 47123247)
2. Ellis, L. M., and Hicklin, D. J. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591
3. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M. J. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237
4. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., Picus, J., Bhargava, P., Mayer, R. J., Schilsky, R. L., and Goldberg, R. M. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622
5. Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603
6. Smith, R. A., Bosonnet, L., Ghaneh, P., Raraty, M., Sutton, R., Campbell, F., and Neoptolemos, J. P. (2008) Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig. Surg. 25, 226-232
7. Koch, M., Dettori, D., Van Nuffelen, A., Souffreau, J., Marconcini, L., Wallays, G., Moons, L., Bruyere, F., Oliviero, S., Noel, A., Foidart, J. M., Carmeliet, P., and Dewerchin, M. (2009) VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J. Pathol. 219, 356-364
8. Kurahara, H., Takao, S., Maemura, K., Shinchi, H., Natsugoe, S., and Aikou, T. (2004) Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin. Cancer Res. 10, 8413-8420 (Pubitemid 40053404)
9. Augustin, H. G., Koh, G. Y., Thurston, G., and Alitalo, K. (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell. Biol. 10, 165-177
10. Lewis, C. E., De Palma, M., and Naldini, L. (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 67, 8429-8432 (Pubitemid 47437413)
11. Shim, W. S., Ho, I. A., and Wong, P. E. (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 5, 655-665 (Pubitemid 47105484)
12. Yuan, H. T., Khankin, E. V., Karumanchi, S. A., and Parikh, S. M. (2009) Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol. Cell. Biol. 29, 2011-2022
13. Carlson, T. R., Feng, Y., Maisonpierre, P. C., Mrksich, M., and Morla, A. O. (2001) Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 276, 26516-26525
14. Hu, B., Jarzynka, M. J., Guo, P., Imanishi, Y., Schlaepfer, D. D., and Cheng, S. Y. (2006) Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 66, 775-783 (Pubitemid 43165942)
15. Imanishi, Y., Hu, B., Jarzynka, M. J., Guo, P., Elishaev, E., Bar-Joseph, I., and Cheng, S. Y. (2007) Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 67, 4254-4263 (Pubitemid 46815072)
16. Yoshiji, H., Kuriyama, S., Noguchi, R., Yoshii, J., Ikenaka, Y., Yanase, K., Namisaki, T., Kitade, M., Uemura, M., Masaki, T., and Fukui, H. (2005) Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 54, 1768-1775 (Pubitemid 41697677)
17. Sarraf-Yazdi, S., Mi, J., Moeller, B. J., Niu, X., White, R. R., Kontos, C. D., Sullenger, B. A., Dewhirst, M. W., and Clary, B. M. (2008) Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J. Surg. Res. 146, 16-23 (Pubitemid 351442931)
18. Lee, O. H., Fueyo, J., Xu, J., Yung, W. K., Lemoine, M. G., Lang, F. F., Bekele, B. N., Zhou, X., Alonso, M. A., Aldape, K. D., Fuller, G. N., and Gomez-Manzano, C. (2006) Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8, 419-428 (Pubitemid 43830749)
19. Fiedler, U., and Augustin, H. G. (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 27, 552-558 (Pubitemid 44780853)
20. Reiss, Y., Knedla, A., Tal, A. O., Schmidt, M. H., Jugold, M., Kiessling, F., Burger, A. M., Wolburg, H., Deutsch, U., and Plate, K. H. (2009) Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J. Pathol. 217, 571-580
21. Kumpers, P., Koenecke, C., Hecker, H., Hellpap, J., Horn, R., Verhagen, W., Buchholz, S., Hertenstein, B., Krauter, J., Eder, M., David, S., Gohring, G., Haller, H., and Ganser, A. (2008) Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 112, 2139-2148
22. Park, J. H., Park, K. J., Kim, Y. S., Sheen, S. S., Lee, K. S., Lee, H. N., Oh, Y. J., and Hwang, S. C. (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132, 200-206
23. Wang, J., Wu, K., Zhang, D., Tang, H., Xie, H., Hong, L., Pan, Y., Lan, M., Hu, S., Ning, X., and Fan, D. (2005) Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem. Biophys. Res. Commun. 337, 386-393 (Pubitemid 41393807)
24. Detjen, K. M., Rieke, S., Deters, A., Schulz, P., Rexin, A., Vollmer, S., Hauff, P., Wiedenmann, B., Pavel, M., and Scholz, A. (2010) Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin. Cancer Res. 16, 420-429
25. Durkin, A. J., Bloomston, M., Yeatman, T. J., Gilbert-Barness, E., Cojita, D., Rosemurgy, A. S., and Zervos, E. E. (2004) Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J. Am. Coll. Surg. 199, 724-731 (Pubitemid 39410571)
26. Hegen, A., Koidl, S., Weindel, K., Marme, D., Augustin, H. G., and Fiedler, U. (2004) Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler. Thromb. Vasc. Biol. 24, 1803-1809 (Pubitemid 39350295)
27. Fischer, C., Sanchez-Ruderisch, H., Welzel, M., Wiedenmann, B., Sakai, T., Andre, S., Gabius, H. J., Khachigian, L., Detjen, K. M., and Rosewicz, S. (2005) Galectin-1 interacts with the α5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J. Biol. Chem. 280, 37266-37277 (Pubitemid 41587811)
28. Audero, E., Cascone, I., Zanon, I., Previtali, S. C., Piva, R., Schiffer, D., and Bussolino, F. (2001) Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: in vivo and in vitro studies. Arterioscler. Thromb. Vasc. Biol. 21, 536-541 (Pubitemid 32323385)
29. Schulz, P., Scholz, A., Rexin, A., Hauff, P., Schirner, M., Wiedenmann, B., and Detjen, K. (2008) Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. Br. J. Cancer 99, 110-117 (Pubitemid 351920244)
30. Von Marschall, Z., Scholz, A., Stacker, S. A., Achen, M. G., Jackson, D. G., Alves, F., Schirner, M., Haberey, M., Thierauch, K. H., Wiedenmann, B., and Rosewicz, S. (2005) Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int. J. Oncol. 27, 669-679
31. Simon, M. P., Tournaire, R., and Pouyssegur, J. (2008) The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell. Physiol. 217, 809-818
32. Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., and Augustin, H. G. (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 15, 1384-1392
33. Villeneuve, J., Galarneau, H., Beaudet, M. J., Tremblay, P., Chernomoretz, A., and Vallieres, L. (2008) Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment. Brain Pathol. 18, 401-414 (Pubitemid 351782849)
34. Stratmann, A., Acker, T., Burger, A. M., Amann, K., Risau, W., and Plate, K. H. (2001) Differential inhibition of tumor angiogenesis by Tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int. J. Cancer 91, 273-282 (Pubitemid 32049618)
35. Sfiligoi, C., de Luca, A., Cascone, I., Sorbello, V., Fuso, L., Ponzone, R., Biglia, N., Audero, E., Arisio, R., Bussolino, F., Sismondi, P., and De Bortoli, M. (2003) Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer 103, 466-474 (Pubitemid 36020220)
36. Jo, M. J., Lee, J. H., Nam, B. H., Kook, M. C., Ryu, K. W., Choi, I. J., Kim, Y. W., and Bae, J. M. (2009) Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann. Surg. Oncol. 16, 2052-2057
37. Morrissey, C., True, L. D., Roudier, M. P., Coleman, I. M., Hawley, S., Nelson, P. S., Coleman, R., Wang, Y. C., Corey, E., Lange, P. H., Higano, C. S., and Vessella, R. L. (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin. Exp. Metastasis 25, 377-388
38. Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., Suri, C., Campochiaro, P. A., Wiegand, S. J., and Yancopoulos, G. D. (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell. 3, 411-423
39. Ahmad, S. A., Liu, W., Jung, Y. D., Fan, F., Wilson, M., Reinmuth, N., Shaheen, R. M., Bucana, C. D., and Ellis, L. M. (2001) The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 61, 1255-1259 (Pubitemid 34292536)
40. Stoeltzing, O., Ahmad, S. A., Liu, W., McCarty, M. F., Parikh, A. A., Fan, F., Reinmuth, N., Bucana, C. D., and Ellis, L. M. (2002) Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br. J. Cancer 87, 1182-1187 (Pubitemid 35422722)
41. Stoeltzing, O., Ahmad, S. A., Liu, W., McCarty, M. F., Wey, J. S., Parikh, A. A., Fan, F., Reinmuth, N., Kawaguchi, M., Bucana, C. D., and Ellis, L. M. (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63, 3370-3377 (Pubitemid 36735897)
42. Tian, S., Hayes, A. J., Metheny-Barlow, L. J., and Li, L. Y. (2002) Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br. J. Cancer 86, 645-651 (Pubitemid 34185105)
43. Chen, X., Fu, W., Tung, C. E., and Ward, N. L. (2009) Angiopoietin-1 induces neurite outgrowth of PC12 cells in a Tie2-independent, β1-integrin-dependent manner. Neurosci. Res. 64, 348-354
44. Mehlen, P., and Fearon, E. R. (2004) Role of the dependence receptor DCC in colorectal cancer pathogenesis. J. Clin. Oncol. 22, 3420-3428 (Pubitemid 41103701)
45. Seraj, M. J., Samant, R. S., Verderame, M. F., and Welch, D. R. (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60, 2764-2769 (Pubitemid 30395788)
46. Sotgia, F., Williams, T. M., Schubert, W., Medina, F., Minetti, C., Pestell, R. G., and Lisanti, M. P. (2006) Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol. 168, 292-309 (Pubitemid 43062581)
47. Jo, M., Lester, R. D., Montel, V., Eastman, B., Takimoto, S., and Gonias, S. L. (2009) Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J. Biol. Chem. 284, 22825-22833
48. Huang, H., Bhat, A., Woodnutt, G., and Lappe, R. (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10, 575-585
49. Mita, A. C., Takimoto, C. H., Mita, M., Tolcher, A., Sankhala, K., Sarantopoulos, J., Valdivieso, M., Wood, L., Rasmussen, E., Sun, Y. N., Zhong, Z. D., Bass, M. B., Le, N., and LoRusso, P. (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin. Cancer Res. 16, 3044-3056
50. Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., Hawkins, N., Rosenfeld, R., Davy, E., Graham, K., Jacobsen, F., Stevenson, S., Ho, J., Chen, Q., Hartmann, T., Michaels, M., Kelley, M., Li, L., Sitney, K., Martin, F., Sun, J. R., Zhang, N., Lu, J., Estrada, J., Kumar, R., Coxon, A., Kaufman, S., Pretorius, J., Scully, S., Cattley, R., Payton, M., Coats, S., Nguyen, L., Desilva, B., Ndifor, A., Hayward, I., Radinsky, R., Boone, T., and Kendall, R. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516 (Pubitemid 39469986)
51. Karlan, B. Y., Oza, A. M., Hansen, V. L., Richardson, G. E., Provencher, D. M., and Ghatagne, P. (2010) Randomized, double-blind, placebo-controlled phase II study of AMG 368 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J. Clin. Oncol. 28, abstr. 5000
52. Hashizume, H., Falcon, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., and McDonald, D. M. (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70, 2213-2223
53. Brown, J. L., Cao, Z. A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M., Emery, S., McDermott, B., Pablo, L., McCoon, P., Bedian, V., and Blakey, D. C. (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 9, 145-156